Pyramid Comment

This journal takes an alternative view on current affairs and other subjects. The approach is likely to be contentious and is arguably speculative. The content of any article is also a reminder of the status of those affairs at that date. All comments have been disabled. Any and all unsolicited or unauthorised links are absolutely disavowed.

Sunday, November 19, 2006


Original posting, August 2006

Asthma patients receiving treatment: 5.2 million people (1.1m children + 4.1m adults).
Deaths: 1,381 in 2004.

Those suffering severe symptoms: 2.6m.

No effective existing medication: 500,000 serious attacks.

Deaths: 1381/5200000 = 0.027%
Severe symptoms: 500,000/2600000 = 19.2%

Something not right here. A way of manufacturing and delivering the newly identified family of immune proteins, lambda-interferons, must be developed before they can be tested as a therapy. Enter Synairgen, a biotechnology company.

Grants forthcoming? Work already done?

Well, start asking yourself questions. Fascinating how news like this always breaks when there is a 'cure' just around the corner.